Abstract:

Objective:The purpose of this study was to apply the anti-human VEGF monoclonal antibody E11, which was generated against a synthetic peptide from the NH2of the human VEGF (residues 1-26), to againstVEGF in buccal carcinoma, and to ex- amine the inhibition effect of the antibody on the carcinoma growth.Methods:E11was hypodermic and celiac injected, with 200 Lg each from the first to the 15th day, into BALBPc nuPnu mice, whichwere transplanted with human buccal carcinoma. The sa- line was injected as the negative control. Mice were killed on the 18th day. The tumor weight was determined and the inhibition rate was calculated.Results:The growth of BCaCD885 carcinomawas dramatically inhibited in the E11group. There was a signifi- cant difference in tumorweight between the saline group and the E11groups during the observation period. The tumor growth inhi- bition rate in the mice hypodermically injected with E11reached 69.9%.Conclusion:The anti-human VEGFmonoclonal antibody E11significantly inhibits tumor growth by blocking the action of VEGF, and without obvious side effects, therefore the anti-human VEGF monoclonal antibody could be applied clinically in the anti-angiogenic treatment of solid tumors.

Key words: vascular endothelial growth factor, tumor growth, angiogenesis, monoclonal antibodies, animal models